| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $21.6M | +135.3% |
| SG&A Expense | $7.3M | +7.8% |
| Operating Income | -$28.8M | -81.3% |
| Pre-tax Income | -$27.6M | -121.3% |
| Income Tax | $0 | — |
| Net Income | -$27.6M | -121.3% |
| EPS (Basic) | -$3.56 | -44.7% |
| EPS (Diluted) | -$3.56 | -44.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $16.0M | -28.6% |
| Current Assets | $16.1M | -28.6% |
| Total Assets | $16.3M | -28.6% |
| Current Liabilities | $8.3M | +38.8% |
| Total Liabilities | $8.3M | +36.6% |
| Stockholders' Equity | $7.9M | -52.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$24.7M | -128.8% |
| Capital Expenditures | $8K | -84.0% |
| Investing Cash Flow | -$8K | +84.0% |
| Financing Cash Flow | $18.3M | — |
| Free Cash Flow | -$24.7M | -127.8% |